[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"facial-vitality-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:facial-vitality-impairment":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100637390","efficacy-and-safety-of-high-dose-oral-35-kda-hyaluronan-for-aesthetic-improvement-100637390",false,"NCT07583108","Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan (HA35) in Subjects Seeking Facial and Body Aesthetic Improvement","HA35-ORAL","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Seeking non-invasive improvement of facial\u002Fbody appearance\n* Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin\n* Ability to complete VAS assessments and study logs\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Aesthetic\u002Fweight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks\n* Significant weight change (\\>3 kg) within 3 months\n* Uncontrolled systemic disease (diabetes, hypertension, etc.)\n* Known hypersensitivity to hyaluronan\n* Pregnant or lactating women\n* Participation in another clinical trial within 30 days",true,"ALL","18 Years","60 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement. Eligible participants will receive 5 g oral HA35 once daily on an empty stomach for 40 consecutive days. The primary objectives are to assess changes in facial and body subcutaneous fullness, inflammatory erythema, facial vitality, and body weight. Safety, gastrointestinal tolerability, and additional exploratory outcomes will be evaluated throughout the intervention period. This is a minimal-risk, oral, non-pharmacological supportive care intervention.",[29,30,31,32,33,34],"Facial Subcutaneous Fullness","Subcutaneous Fat Accumulation","Facial Inflammatory Erythema","Dull Skin","Facial Vitality Impairment","Body Weight Management",[36,37,38,39,40,41,42,43,44,45],"Hyaluronan","35 kDa Hyaluronan","HA35","Oral Administration","Subcutaneous Fat Reduction","Facial Erythema","Facial Vitality","Body Weight","Non-invasive Aesthetic","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-07",{"date":49,"type":50},"2026-05-13","ACTUAL",{"date":52,"type":23},"2026-05-20",{"date":54,"type":23},"2026-07-20",{"name":56,"class":57},"Nakhia Impex LLC","INDUSTRY"]